Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis

NCT00750750 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT00750750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00750750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis
Lead sponsor
Organon and Co
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2003
Completion date
September 1, 2003
Enrollment
981 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute rhinosinusitis